Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
13,155,511
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
22,966
-
Shares change
-
+22,966
-
Total reported value, excl. options
-
$209,366
-
Value change
-
+$209,366
-
Number of buys
-
12
-
Price
-
$9.00
Significant Holders of Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) as of Q4 2023
12 filings reported holding AVTX - Avalo Therapeutics, Inc. - Class A Common Stock as of Q4 2023.
Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,966 shares
of 13,155,511 outstanding shares and own 0.17% of the company stock.
Largest 10 shareholders include BlackRock Inc. (15,876 shares), NATIXIS (4,604 shares), Tower Research Capital LLC (TRC) (1,766 shares), FNY Investment Advisers, LLC (522 shares), ROYAL BANK OF CANADA (138 shares), MORGAN STANLEY (44 shares), WELLS FARGO & COMPANY/MN (8 shares), JPMORGAN CHASE & CO (2 shares), UBS Group AG (2 shares), and GROUP ONE TRADING, L.P. (2 shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.